anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dosage must be individualized. Blood pressure response is dose related over the range of 2 to 32 mg. The usual recommended starting dose of ATACAND is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. ATACAND can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg. Larger doses do not appear to have a greater effect, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks, and maximal blood pressure reduction is generally obtained within 4 to 6 weeks of treatment with ATACAND.

No initial dosage adjustment is necessary for elderly patients, for patients with mildly impaired renal function, or for patients with mildly impaired hepatic function [see CLINICAL PHARMACOLOGY (12.3)]. In patients with moderate hepatic impairment, consideration should be given to initiation of ATACAND at a lower dose [see CLINICAL PHARMACOLOGY (12.3)]. For patients with possible depletion of intravascular volume (eg, patients treated with diuretics, particularly those with impaired renal function), ATACAND should be initiated under close medical supervision and consideration should be given to administration of a lower dose [see WARNINGS AND PRECAUTIONS (5.3)]. 

ATACAND may be administered with or without food.

If blood pressure is not controlled by ATACAND alone, a diuretic may be added. ATACAND may be administered with other antihypertensive agents.
Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
This group performed the same protocol as SMRS group, as well as include the following strengthening exercises: the supine chin tuck (SCT), upper thoracic-lower cervical extension (UTLCE) using an exercise band that provided 5.5 pounds of resistance, and a single-arm row with trunk rotation (SARTR) using exercise tubing that provided 20 pounds of resistance. The SCT was progressed in 3 phases: Week 1: chin tuck held 2 sec., 5 reps. Week 2: same as week 1, but included us of a towel roll placed under the head. Wks. 3 and 4: chin tuck with head lift 1 in., 2 sec. hold. UTLCE: neck extension with exercise band, held 2 sec. SARTR: single arm row with trunk rotation was performed in a controlled and fluid manner using a self-selected speed. The UTLCE and SARTR were performed with 1 X 10 reps for wks 1-2 and progressed to 2 X10 reps in wks 3-4. Strengthening exercises were performed 3x/wk. for 4 wks.
The invention relates to an amphoteric co-continuous polymer network. The amphoteric co-continuous polymer network is prepared through chemical crosslinking reaction by using  an organic siloxane polymer as a raw material and N-isopropyl acrylamide as a reactant monomer to generate a graft copolymer. The gel dissolving rate in water is in the range of 0-10%, the swelling rate in water is in the range of 20-50%, and the oxygen transmissibility is in the range of 150-600 barrers. The invention also relates to a method for producing the amphoteric co-continuous polymer network. The method comprises the following steps: (1) synthesis of methacrylic acid-3-(1,1,3,3-tetramethyldisiloxane)propyl ester; (2) preparation of a modified unsaturated organic siloxane polymer mixture; (3) synthesis of the graft copolymer; and (4) preparation of amphoteric co-continuous network. The amphoteric co-continuous polymer network is used for biomedical materials,  including contact lens, artificial organs, controlled-release drug carriers etc.
This randomized, open-label, dose escalation, crossover study was conducted at a contract clinical research facility. Three single doses were evaluated using three cohorts (N=12 per cohort). Study doses were as follows: cohort 1 - 7.5mg IV and 10mg PO, cohort 2 - 11.5mg IV and 15mg PO, and cohort 3 - 15mg IV and 20mg PO. The IV baclofen doses for this trial were based on a 75% bioavailability observed in a previous low dose study.16 The oral formulation of the study drug used in this trial was 10mg baclofen tablet (Teva Pharmaceutical Industries Ltd.) and is commercially available. The intravenous formulation was 2mg/mL solution manufactured by Aptuit LLC. for this study. IV infusions were administered over 10 minutes. In addition, cohort 3 received 15mg over a 60-minute infusion. There was a minimum 48-hour washout period between doses. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with a high unmet medical need. The prevalence of HS reported in most studies is 1-2%, although it is likely to be under-reported and estimates vary globally owing to variance in data collection methods, ethnicity, geographical location and under-diagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses and draining tunnels commonly affecting the axillary, anogenital, inguinal and perianal/gluteal areas. Over time, chronic uncontrolled inflammation results in irreversible tissue destruction and scarring. Although the pathophysiology of HS has not been fully elucidated, the tumour necrosis factor (TNF)-α and interleukin (IL)-17 pathways have an important role, involving multiple cytokines. Currently, treatment options include topical medications; systemic therapies, including repeated and/or rotational courses of systemic antibiotics, retinoids and hormonal therapies; and various surgical procedures. The anti-TNF-α antibody adalimumab is currently the only biologic approved by both the US Food and Drug Administration and the European Medicines Agency for HS; however, its efficacy varies, with a clinical response reported in approximately 50% of patients in phase III trials. HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged, and agents targeting the IL-17 and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways are the most advanced in ongoing or completed phase III clinical trials. Alongside limited therapeutic options, significant challenges remain in terms of diagnosis and disease management, with a need for better treatment outcomes. Other unmet needs include significant diagnostic delays, thus missing the therapeutic 'window of opportunity'; the lack of standardized outcome measures in clinical trials; and the lack of established, well-defined disease phenotypes and biomarkers.
<P>PROBLEM TO BE SOLVED: To provide a molded product of a foamable chlorinated isocyanuric acid, having excellent preservation stability, capable of reducing the abrasion of a mortar and a pounder used as a mold at pressure forming thereof, preventing the surfaces of the mortar and the pounder from being damaged, and enabling the use of a lubricant to be reduced.  <P>SOLUTION: The molded product of the foamable chlorinated isocyanuric acid is obtained by subjecting a formulated product of 100 pts. wt. chlorinated isocyanuric acid, 50-200 pts. wt. organic acid, 50-200 pts. wt. carbonic acid salt and 10-100 pts. wt. sodium sulfate having ≥45 and <355 μm particle diameter to the pressure forming.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Adverse pregnancy outcomes (APOs) affect a large proportion of pregnancies and represent an important cause of morbidity and mortality worldwide. Yet the pathophysiology of APOs is poorly understood, limiting our ability to prevent and treat these conditions. To search for genetic markers of maternal risk for four APOs, we performed multi-ancestry genome-wide association studies (GWAS) for pregnancy loss, gestational length, gestational diabetes, and preeclampsia. We clustered participants by their genetic ancestry and focused our analyses on three sub-cohorts with the largest sample sizes: European, African, and Admixed American. Association tests were carried out separately for each sub-cohort and then meta-analyzed together. Two novel loci were significantly associated with an increased risk of pregnancy loss: a cluster of SNPs located downstream of the TRMU gene (top SNP: rs142795512), and the SNP rs62021480 near RGMA. In the GWAS of gestational length we identified two new variants, rs2550487 and rs58548906 near WFDC1 and AC005052.1, respectively. Lastly, three new loci were significantly associated with gestational diabetes (top SNPs: rs72956265, rs10890563, rs79596863), located on or near ZBTB20, GUCY1A2, and RPL7P20, respectively. Fourteen loci previously correlated with preterm birth, gestational diabetes, and preeclampsia were found to be associated with these outcomes as well.
A kidney stone is a solid formation that can lead to kidney failure, severe pain, and reduced quality of life from urinary system blockages. While medical experts can interpret kidney-ureter-bladder (KUB) X-ray images, specific images pose challenges for human detection, requiring significant analysis time. Consequently, developing a detection system becomes crucial for accurately classifying KUB X-ray images. This article applies a transfer learning (TL) model with a pre-trained VGG16 empowered with explainable artificial intelligence (XAI) to establish a system that takes KUB X-ray images and accurately categorizes them as kidney stones or normal cases. The findings demonstrate that the model achieves a testing accuracy of 97.41% in identifying kidney stones or normal KUB X-rays in the dataset used. VGG16 model delivers highly accurate predictions but lacks fairness and explainability in their decision-making process. This study incorporates the Layer-Wise Relevance Propagation (LRP) technique, an explainable artificial intelligence (XAI) technique, to enhance the transparency and effectiveness of the model to address this concern. The XAI technique, specifically LRP, increases the model's fairness and transparency, facilitating human comprehension of the predictions. Consequently, XAI can play an important role in assisting doctors with the accurate identification of kidney stones, thereby facilitating the execution of effective treatment strategies.
Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
The active control intervention will include stretching and toning exercises, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
This is a double-blind, placebo-controlled, parallel-group, randomized clinical trial in men, 40-70 years of age, who present with mild to moderate erectile dysfunction and have androgen deficiency defined as serum total testosterone level below 300 ng/dL, measured by liquid chromatography tandem mass spectrometry, LC-MS/MS (15) and/or free testosterone level (measured by equilibrium dialysis) below 50 pg/ml. Sexual function assessments will include validated erectile function questionnaires (IIEF), sexual activity diaries, sexual desire, partner interaction and intimacy, affects balance scale, mood, ED-related quality of life, and penile rigidity in response to a visual erotic stimulus. The initial assessment will be made prior to treatment with sildenafil citrate, i.e., in subjects who are naïve to or withdrawn from PDE5 inhibitors and/or testosterone. Participants will then be allotted three sildenafil citrate tablets per week (12 pills per month), but will not use more than one tablet within any 24-hour period. During the Sildenafil-Dose Optimization period, subjects naïve to sildenafil citrate will start with a 50 mg dose. Those who have used sildenafil citrate in the past will take the same dose that was found to be efficacious for them. After three weeks, the dose of sildenafil citrate will be increased to 100-mg in non-responders. For those who cannot tolerate the 50-mg dose, a dose of 25 mg will be given. After three weeks on the optimized dose of sildenafil citrate, subjects will undergo a second evaluation of sexual function. They will then be randomly assigned to receive this optimized dose of sildenafil citrate with either placebo gel (15 g per day) or active testosterone gel (10 g active gel + 5 g placebo gel per day). The daily dose of active testosterone gel was selected to increase average serum into the upper-half of the normal range for healthy, young men (e.g., 500-1000 ng/dL). In order to assure that serum testosterone levels are in the target range (500-1000 ng/dL), testosterone dose will be adjusted by an unblinded individual two to three weeks after initiation of testosterone/placebo treatment, based on the measurement of serum testosterone levels. If the average testosterone level is less than 500 ng/dL, the daily dose will be increased to 15g of active gel. If the average testosterone is greater than 1,000 ng/dL, the daily dose will be decreased to 5 g of active gel (and 10 g of placebo gel). This dose adjustment will take effect at week 4 (day 28) of treatment. Subjects will be treated for an additional 12-weeks with sildenafil citrate and the optimized dose of testosterone gel or placebo gel. Sexual function will be evaluated at the end of this treatment period.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic technique effective against novel influenza infection.  <P>SOLUTION: A pharmaceutical composition containing an anti-plasmin agent as an active ingredient is used for treating novel influenza infection. Sufficient therapeutic effect can be achieved by administering the anti-plasmin agent via inhalation at initial stage of respiratory failure caused by activated alveolar macrophage. The agent requires delivery to the lower respiratory tract by oral or nasal inhalation. The anti-plasmin agent used here is e.g. tranexamic acid and ε-aminocaproic acid.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Participants in this study group will receive daily COVID-19 symptom (CS) text-based monitoring system to prompt more rapid testing at the onset of symptoms. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
A senna preparation is prepared by adsorbing the glycosides from a liquid extract of senna by forming and precipitating aluminium hydroxide in situ in the extract.  An aqueous solution of a soluble aluminium salt e.g. sulphate, ammonia alum or potash alum is added to the liquid senna extract followed by an aqueous solution of an alkali especially sodium, potassium or ammonium hydroxide to produce a pH of 6,8 to 7,2 and the precipitated aluminium hydroxide with adsorbed glycosides is separated and dried at a temperature below 55 DEG C. The powder so produced may be incorporated in tablets, plain or coated, pills, chocolate, granules and other oral preparations. Alternatively, the glycosides may be eluted from the adsorbate by means of acid or alkali.  The extract may be made from whole pods, ground or unground or from deseeded pods.  Water is the preferred solvent but aqueous methanol, aqueous ethanol or aqueous acetone may also be used.
Oltipraz (OPZ) is a synthetic dithiolethione and is considered a novel activator of nuclear factor E2-related factor 2 (Nrf2). Increasing evidence indicates that Nrf2 protects against cerebral ischemia/reperfusion (I/R) injury by antagonizing ferroptosis and lipid peroxidation. However, the protective effects of OPZ on cerebral I/R injury remain to be elucidated. We investigated the in vitro and in vivo neuroprotective effects of OPZ. Mice were subjected to middle cerebral artery occlusion/reperfusion (MCAO/R) to construct an in vivo model and PC12 cells were exposed to oxygen and glucose deprivation/reoxygenation (OGD/R) to establish an in vitro model. OPZ administration reduced the infarct volume and brain water content, and alleviated the neurological deficit of MCAO/R mice. Moreover, OPZ ameliorated MCAO/R-induced oxidative stress by decreasing the levels of 4-HNE and MDA and increasing the activities of SOD and GSH. We also found that OPZ ameliorated MCAO/R-induced ferroptosis by increasing SLC7A11 and GPX4 protein expression and downregulating ACSL4 protein expression. Similarly, the in vitro results revealed that OGD/R-induced oxidative stress and ferroptosis. Finally, mechanistic analysis revealed that OPZ significantly upregulated the Nrf2 expression and Nrf2 knockout (Nrf2 KO) abolished the OPZ-mediated protective effects. Taken together, these findings demonstrate that OPZ ameliorates cerebral I/R injury by suppressing the oxidative stress and ferroptosis.
Previous research has demonstrated a lack of resident training in communication at the end of life. This can lead to anxiety on the part of residents and poor experiences with these conversations. Residents at UCSF, and affiliated sites, participate in a daily formal teaching session from 12-1 pm and an informal case conference, known as Morning Report, from 7:30-8:30 am (8-9 am at VAMC). We propose to administer a pre-intervention survey to residents to assess knowledge and attitudes regarding communication at the end of life. Over two months, residents will receive one lecture during the noon session. Clinical cases will be presented for discussion during three sessions of morning report. All sessions are voluntary and take place at all three training sites, UCSF, SFGH, and the VAMC. As residents rotate every two months between the inpatient and outpatient settings, the intervention will be repeated once to ensure that the majority of residents have the opportunity to participate. A post-intervention survey, identical to the pre-intervention survey, will be administered to assess for impact of the educational intervention. This project only involves UCSF Internal Medicine residents. No patients will be involved in this study.
The invention discloses a pharmaceutical composition for treating herpes zoster and a preparation method thereof. The pharmaceutical composition for treating herpes zoster comprises an oral medicine and an external medicine, wherein the oral medicine comprises honeysuckle flower, taraxacum, Plantain seed, fiveleaf akebia, radix rehmanniae, radix bupleuri, gentian, isatis leaf, Eurya chinensis root and the like; and the external medicine comprises Eurya chinensis root, white alum, taraxacum, centipede and the like. The preparation method is implemented by decocting with water to obtain a pasty ointment. The pharmaceutical composition has the main functions of clearing away the liver-fire and removing dampness by diuresis, and can completely cure herpes zoster without relapse; the healed patient does not have the pain symptom; and thus, the pharmaceutical composition can treat both the symptoms and root causes of herpes zoster, thereby achieving the goal of complete cure and obvious effect. The cure rate is up to higher than 90%. The preparation method is simple and easy to implement.
The invention provides a preparation for treating coronary heart disease and a preparation method of the preparation, which is prepared from the following raw materials: american ginseng, pseudo-ginseng, amber, pollen typhae and rhizoma nardostachyos. The preparation is prepared through the medicines according to regulations of pharmacopeia. The raw medicines for the preparation are cleaned, then processed and baked based on types, and finally porphyrized (screened by a (120-150)-mesh sieve) to obtain the preparation. The preparation follows the principles of flexibly utilizing assistant and guide based on the prescription of traditional Chinese medicine, high-level traditional Chinese medicines are selected; through clinical observation, the coronary heart disease has the main symptoms shown as deficient root (insufficiency of the heart-Qi) with overdo superficial (heart blood stasis syndrome); the american ginseng and the pseudo-ginseng are adopted for tonifying Qi and enhancing vitality; and the amber is used for lowering heart fire and calming nerves. The preparation has the advantages of being precise and appropriate in medicine use, curing diseases based on pathogenesis and being safe to take, and overcomes the shortcomings of other medicines. The preparation has the beneficial effect that a patent with coronary heart disease more than 10 years with symptoms such as stenocardia, chest stuffiness and breathe hard in clinic always takes the preparation for about 2 hours to gradually relieve or remove the symptoms. The preparation brings no adverse reaction and toxic and side effects during tracking and observing special cases; the frequency of attacks is obviously reduced after taking a course (one month) in general, the times of attacks are highly reduced, and therefore the effects of highly tonifying Qi and dredging collaterals are realized; and the preparation has the advantages of being safe, non-toxic, convenient to take, and simple in manufacture process.
The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of \[11C\]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second \[11C\]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in \[11C\]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
Aqueous solutions containing alkylamido betaines and certain water-soluble inorganic or organic salts provide compositions of remarkably high viscosities. The inorganic salts suitable for this purpose are the sulfates of metals from Groups IA, IIA, IIB, and IIIA of the period table; sulfates of non-metallic ions; and alkali metal carbonates. Organic salts suitable in the present compositions include the citrates, tartrates, succinates, and carboxymethyloxysuccinates of metals from Groups IA, IIA, IIB and IIIA of the period table and the citrates, tartrates, succinates and carboxymethyloxysuccinates of ammonium ions. These salts have a synergistic viscosity-building effect on aqueous compositions containing alkylamido betaines in combination with micelle-forming anionic surfactants. Other salts increase the viscosity of aqueous solutions containing alkylamido betaines only in the presence of anionic surfactants. Suitable inorganic salts in this category include sulfates of metals from Group IB of the period table; alums; alkali metal sesquicarbonates; alkali metal tripolyphosphates and pyrophosphates; salts of halogen acids selected from the group consisting of potassium chloride and ammonium chloride; and alkali metal silicates. Suitable organic salts in this category include alkali metal salts of acetic acid and alkali metal salts of nitrilotriacetic acid.